Clinical Trial of Radioimmunoimaging of Lymph Node Metastasis in Esophageal Carcinoma
10.3321/j.issn:1000-467X.2001.02.016
- VernacularTitle:食管癌转移淋巴结放免显像定位的临床试验
- Author:
Peng LIN
1
;
Tie-Hua RONG
;
Wei FAN
;
Guo-Liang XU
;
Chang-Zheng LIU
;
Jun-Fang HE
;
Chang-Sheng LIANG
;
Le-He LIU
Author Information
1. Sun Yat-sen University of Medical Sciences
- From:Chinese Journal of Cancer
2001;20(2):183-186
- CountryChina
- Language:Chinese
-
Abstract:
Objective: The current study was designed to evaluate the clinical application of radioimmunoimaging(RII) for lymph node metastasis in esophageal carcinoma. Methods:1)131I was used to label McAb G9(specific to cellular membrane antigen of human esophageal carcinoma) and form labeling compound 131I-G9. Administration of 131I-G9 in esophagus submucosally with a specific injector for the purpose of submucosal injection via endoscopies in preoperative patients with squamous cell carcinoma of thoracic esophagus followed by RII. 2)The samples of dissected lymph node were used for detection of radioactivity. Results: 1)The pictures at 48 h showed that small radioactivity concentrated dots appeared dispersedly in mediastinum and upper abdomen around esophagus and cardiac gastric. The lymph nodes were considered metastatic in above regions. 2)The pathological results of the lymph nodes dissected compared to the RII result. The metastatic lymph nodes were found in the regions of dispersedly concentrated radioactivity, while no metastatic lymph nodes could be found in the radioactivity free regions. 3)After counting for radioactivity, lymph node metastases showed higher antibody uptake than the non-metastases lymph nodes. The difference was statistically significant. Conclusion: 131I-G9 may be used to locate metastatic lymph nodes in patients with esophageal carcinoma.
